 | • レポートコード：MRC2-11QY11452 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は市中肺炎（CAP）のグローバル市場について調査・分析したレポートです。種類別（胸部X線/X線撮影、喀痰グラム染色/培養、血液培養）市場規模、用途別（病院・クリニック、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別市中肺炎（CAP）の競争状況、市場シェア ・世界の市中肺炎（CAP）市場：種類別市場規模 2015年-2020年（胸部X線/X線撮影、喀痰グラム染色/培養、血液培養） ・世界の市中肺炎（CAP）市場：種類別市場規模予測 2021年-2026年（胸部X線/X線撮影、喀痰グラム染色/培養、血液培養） ・世界の市中肺炎（CAP）市場：用途別市場規模 2015年-2020年（病院・クリニック、その他） ・世界の市中肺炎（CAP）市場：用途別市場規模予測 2021年-2026年（病院・クリニック、その他） ・北米の市中肺炎（CAP）市場分析：米国、カナダ ・ヨーロッパの市中肺炎（CAP）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの市中肺炎（CAP）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の市中肺炎（CAP）市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの市中肺炎（CAP）市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer、Astrazeneca、Bioaegis Therapeutics、Biotest、C10 Pharma、Kyorin Pharmaceutical、Melinta Therapeutics、Merck、Nabriva Therapeutics、Paratek Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person with little contact with the healthcare system.
The market of CAP treatment and diagnosis in further segmented with respect to major geographies of North America, Europe, Asia-Pacific, and Latin America.
Market Analysis and Insights: Global Community Acquired Pneumonia (CAP) Market
The global Community Acquired Pneumonia (CAP) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Community Acquired Pneumonia (CAP) Scope and Market Size
Community Acquired Pneumonia (CAP) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Community Acquired Pneumonia (CAP) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Pfizer
Astrazeneca
Bioaegis Therapeutics
Biotest
C10 Pharma
Kyorin Pharmaceutical
Melinta Therapeutics
Merck
Nabriva Therapeutics
Paratek Pharmaceuticals
Market segment by Type, the product can be split into
Chest X-ray/Radiography
Sputum Gram Stain and/or Culture
Blood Cultures
Market segment by Application, split into
Hospitals and Clinics
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Community Acquired Pneumonia (CAP) Revenue
1.4 Market by Type
1.4.1 Global Community Acquired Pneumonia (CAP) Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chest X-ray/Radiography
1.4.3 Sputum Gram Stain and/or Culture
1.4.4 Blood Cultures
1.5 Market by Application
1.5.1 Global Community Acquired Pneumonia (CAP) Market Share by Application: 2020 VS 2026
1.5.2 Hospitals and Clinics
1.5.3 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Community Acquired Pneumonia (CAP) Market Perspective (2015-2026)
2.2 Global Community Acquired Pneumonia (CAP) Growth Trends by Regions
2.2.1 Community Acquired Pneumonia (CAP) Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Community Acquired Pneumonia (CAP) Historic Market Share by Regions (2015-2020)
2.2.3 Community Acquired Pneumonia (CAP) Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Community Acquired Pneumonia (CAP) Market Growth Strategy
2.3.6 Primary Interviews with Key Community Acquired Pneumonia (CAP) Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Community Acquired Pneumonia (CAP) Players by Market Size
3.1.1 Global Top Community Acquired Pneumonia (CAP) Players by Revenue (2015-2020)
3.1.2 Global Community Acquired Pneumonia (CAP) Revenue Market Share by Players (2015-2020)
3.1.3 Global Community Acquired Pneumonia (CAP) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Community Acquired Pneumonia (CAP) Market Concentration Ratio
3.2.1 Global Community Acquired Pneumonia (CAP) Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Community Acquired Pneumonia (CAP) Revenue in 2019
3.3 Community Acquired Pneumonia (CAP) Key Players Head office and Area Served
3.4 Key Players Community Acquired Pneumonia (CAP) Product Solution and Service
3.5 Date of Enter into Community Acquired Pneumonia (CAP) Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Community Acquired Pneumonia (CAP) Historic Market Size by Type (2015-2020)
4.2 Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020)
5.2 Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Community Acquired Pneumonia (CAP) Market Size (2015-2020)
6.2 Community Acquired Pneumonia (CAP) Key Players in North America (2019-2020)
6.3 North America Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020)
6.4 North America Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020)
7 Europe
7.1 Europe Community Acquired Pneumonia (CAP) Market Size (2015-2020)
7.2 Community Acquired Pneumonia (CAP) Key Players in Europe (2019-2020)
7.3 Europe Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020)
7.4 Europe Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020)
8 China
8.1 China Community Acquired Pneumonia (CAP) Market Size (2015-2020)
8.2 Community Acquired Pneumonia (CAP) Key Players in China (2019-2020)
8.3 China Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020)
8.4 China Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020)
9 Japan
9.1 Japan Community Acquired Pneumonia (CAP) Market Size (2015-2020)
9.2 Community Acquired Pneumonia (CAP) Key Players in Japan (2019-2020)
9.3 Japan Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020)
9.4 Japan Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Community Acquired Pneumonia (CAP) Market Size (2015-2020)
10.2 Community Acquired Pneumonia (CAP) Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020)
10.4 Southeast Asia Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020)
11 India
11.1 India Community Acquired Pneumonia (CAP) Market Size (2015-2020)
11.2 Community Acquired Pneumonia (CAP) Key Players in India (2019-2020)
11.3 India Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020)
11.4 India Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Community Acquired Pneumonia (CAP) Market Size (2015-2020)
12.2 Community Acquired Pneumonia (CAP) Key Players in Central & South America (2019-2020)
12.3 Central & South America Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020)
12.4 Central & South America Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Community Acquired Pneumonia (CAP) Introduction
13.1.4 Pfizer Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Astrazeneca
13.2.1 Astrazeneca Company Details
13.2.2 Astrazeneca Business Overview
13.2.3 Astrazeneca Community Acquired Pneumonia (CAP) Introduction
13.2.4 Astrazeneca Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020)
13.2.5 Astrazeneca Recent Development
13.3 Bioaegis Therapeutics
13.3.1 Bioaegis Therapeutics Company Details
13.3.2 Bioaegis Therapeutics Business Overview
13.3.3 Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Introduction
13.3.4 Bioaegis Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020)
13.3.5 Bioaegis Therapeutics Recent Development
13.4 Biotest
13.4.1 Biotest Company Details
13.4.2 Biotest Business Overview
13.4.3 Biotest Community Acquired Pneumonia (CAP) Introduction
13.4.4 Biotest Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020)
13.4.5 Biotest Recent Development
13.5 C10 Pharma
13.5.1 C10 Pharma Company Details
13.5.2 C10 Pharma Business Overview
13.5.3 C10 Pharma Community Acquired Pneumonia (CAP) Introduction
13.5.4 C10 Pharma Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020)
13.5.5 C10 Pharma Recent Development
13.6 Kyorin Pharmaceutical
13.6.1 Kyorin Pharmaceutical Company Details
13.6.2 Kyorin Pharmaceutical Business Overview
13.6.3 Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Introduction
13.6.4 Kyorin Pharmaceutical Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020)
13.6.5 Kyorin Pharmaceutical Recent Development
13.7 Melinta Therapeutics
13.7.1 Melinta Therapeutics Company Details
13.7.2 Melinta Therapeutics Business Overview
13.7.3 Melinta Therapeutics Community Acquired Pneumonia (CAP) Introduction
13.7.4 Melinta Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020)
13.7.5 Melinta Therapeutics Recent Development
13.8 Merck
13.8.1 Merck Company Details
13.8.2 Merck Business Overview
13.8.3 Merck Community Acquired Pneumonia (CAP) Introduction
13.8.4 Merck Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020)
13.8.5 Merck Recent Development
13.9 Nabriva Therapeutics
13.9.1 Nabriva Therapeutics Company Details
13.9.2 Nabriva Therapeutics Business Overview
13.9.3 Nabriva Therapeutics Community Acquired Pneumonia (CAP) Introduction
13.9.4 Nabriva Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020)
13.9.5 Nabriva Therapeutics Recent Development
13.10 Paratek Pharmaceuticals
13.10.1 Paratek Pharmaceuticals Company Details
13.10.2 Paratek Pharmaceuticals Business Overview
13.10.3 Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Introduction
13.10.4 Paratek Pharmaceuticals Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020)
13.10.5 Paratek Pharmaceuticals Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Community Acquired Pneumonia (CAP) Key Market Segments
Table 2. Key Players Covered: Ranking by Community Acquired Pneumonia (CAP) Revenue
Table 3. Ranking of Global Top Community Acquired Pneumonia (CAP) Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Community Acquired Pneumonia (CAP) Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chest X-ray/Radiography
Table 6. Key Players of Sputum Gram Stain and/or Culture
Table 7. Key Players of Blood Cultures
Table 8. Global Community Acquired Pneumonia (CAP) Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Community Acquired Pneumonia (CAP) Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Community Acquired Pneumonia (CAP) Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Community Acquired Pneumonia (CAP) Market Share by Regions (2015-2020)
Table 12. Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Community Acquired Pneumonia (CAP) Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Community Acquired Pneumonia (CAP) Market Growth Strategy
Table 18. Main Points Interviewed from Key Community Acquired Pneumonia (CAP) Players
Table 19. Global Community Acquired Pneumonia (CAP) Revenue by Players (2015-2020) (Million US$)
Table 20. Global Community Acquired Pneumonia (CAP) Market Share by Players (2015-2020)
Table 21. Global Top Community Acquired Pneumonia (CAP) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Community Acquired Pneumonia (CAP) as of 2019)
Table 22. Global Community Acquired Pneumonia (CAP) by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Community Acquired Pneumonia (CAP) Product Solution and Service
Table 25. Date of Enter into Community Acquired Pneumonia (CAP) Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020) (Million US$)
Table 28. Global Community Acquired Pneumonia (CAP) Market Size Share by Type (2015-2020)
Table 29. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Type (2021-2026)
Table 30. Global Community Acquired Pneumonia (CAP) Market Size Share by Application (2015-2020)
Table 31. Global Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020) (Million US$)
Table 32. Global Community Acquired Pneumonia (CAP) Market Size Share by Application (2021-2026)
Table 33. North America Key Players Community Acquired Pneumonia (CAP) Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Community Acquired Pneumonia (CAP) Market Share (2019-2020)
Table 35. North America Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020) (Million US$)
Table 36. North America Community Acquired Pneumonia (CAP) Market Share by Type (2015-2020)
Table 37. North America Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020) (Million US$)
Table 38. North America Community Acquired Pneumonia (CAP) Market Share by Application (2015-2020)
Table 39. Europe Key Players Community Acquired Pneumonia (CAP) Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Community Acquired Pneumonia (CAP) Market Share (2019-2020)
Table 41. Europe Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Community Acquired Pneumonia (CAP) Market Share by Type (2015-2020)
Table 43. Europe Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Community Acquired Pneumonia (CAP) Market Share by Application (2015-2020)
Table 45. China Key Players Community Acquired Pneumonia (CAP) Revenue (2019-2020) (Million US$)
Table 46. China Key Players Community Acquired Pneumonia (CAP) Market Share (2019-2020)
Table 47. China Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020) (Million US$)
Table 48. China Community Acquired Pneumonia (CAP) Market Share by Type (2015-2020)
Table 49. China Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020) (Million US$)
Table 50. China Community Acquired Pneumonia (CAP) Market Share by Application (2015-2020)
Table 51. Japan Key Players Community Acquired Pneumonia (CAP) Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Community Acquired Pneumonia (CAP) Market Share (2019-2020)
Table 53. Japan Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Community Acquired Pneumonia (CAP) Market Share by Type (2015-2020)
Table 55. Japan Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Community Acquired Pneumonia (CAP) Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Community Acquired Pneumonia (CAP) Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Community Acquired Pneumonia (CAP) Market Share (2019-2020)
Table 59. Southeast Asia Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Community Acquired Pneumonia (CAP) Market Share by Type (2015-2020)
Table 61. Southeast Asia Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Community Acquired Pneumonia (CAP) Market Share by Application (2015-2020)
Table 63. India Key Players Community Acquired Pneumonia (CAP) Revenue (2019-2020) (Million US$)
Table 64. India Key Players Community Acquired Pneumonia (CAP) Market Share (2019-2020)
Table 65. India Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020) (Million US$)
Table 66. India Community Acquired Pneumonia (CAP) Market Share by Type (2015-2020)
Table 67. India Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020) (Million US$)
Table 68. India Community Acquired Pneumonia (CAP) Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Community Acquired Pneumonia (CAP) Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Community Acquired Pneumonia (CAP) Market Share (2019-2020)
Table 71. Central & South America Community Acquired Pneumonia (CAP) Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Community Acquired Pneumonia (CAP) Market Share by Type (2015-2020)
Table 73. Central & South America Community Acquired Pneumonia (CAP) Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Community Acquired Pneumonia (CAP) Market Share by Application (2015-2020)
Table 75. Pfizer Company Details
Table 76. Pfizer Business Overview
Table 77. Pfizer Product
Table 78. Pfizer Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020) (Million US$)
Table 79. Pfizer Recent Development
Table 80. Astrazeneca Company Details
Table 81. Astrazeneca Business Overview
Table 82. Astrazeneca Product
Table 83. Astrazeneca Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020) (Million US$)
Table 84. Astrazeneca Recent Development
Table 85. Bioaegis Therapeutics Company Details
Table 86. Bioaegis Therapeutics Business Overview
Table 87. Bioaegis Therapeutics Product
Table 88. Bioaegis Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020) (Million US$)
Table 89. Bioaegis Therapeutics Recent Development
Table 90. Biotest Company Details
Table 91. Biotest Business Overview
Table 92. Biotest Product
Table 93. Biotest Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020) (Million US$)
Table 94. Biotest Recent Development
Table 95. C10 Pharma Company Details
Table 96. C10 Pharma Business Overview
Table 97. C10 Pharma Product
Table 98. C10 Pharma Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020) (Million US$)
Table 99. C10 Pharma Recent Development
Table 100. Kyorin Pharmaceutical Company Details
Table 101. Kyorin Pharmaceutical Business Overview
Table 102. Kyorin Pharmaceutical Product
Table 103. Kyorin Pharmaceutical Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020) (Million US$)
Table 104. Kyorin Pharmaceutical Recent Development
Table 105. Melinta Therapeutics Company Details
Table 106. Melinta Therapeutics Business Overview
Table 107. Melinta Therapeutics Product
Table 108. Melinta Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020) (Million US$)
Table 109. Melinta Therapeutics Recent Development
Table 110. Merck Business Overview
Table 111. Merck Product
Table 112. Merck Company Details
Table 113. Merck Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020) (Million US$)
Table 114. Merck Recent Development
Table 115. Nabriva Therapeutics Company Details
Table 116. Nabriva Therapeutics Business Overview
Table 117. Nabriva Therapeutics Product
Table 118. Nabriva Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020) (Million US$)
Table 119. Nabriva Therapeutics Recent Development
Table 120. Paratek Pharmaceuticals Company Details
Table 121. Paratek Pharmaceuticals Business Overview
Table 122. Paratek Pharmaceuticals Product
Table 123. Paratek Pharmaceuticals Revenue in Community Acquired Pneumonia (CAP) Business (2015-2020) (Million US$)
Table 124. Paratek Pharmaceuticals Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Community Acquired Pneumonia (CAP) Market Share by Type: 2020 VS 2026
Figure 2. Chest X-ray/Radiography Features
Figure 3. Sputum Gram Stain and/or Culture Features
Figure 4. Blood Cultures Features
Figure 5. Global Community Acquired Pneumonia (CAP) Market Share by Application: 2020 VS 2026
Figure 6. Hospitals and Clinics Case Studies
Figure 7. Others Case Studies
Figure 8. Community Acquired Pneumonia (CAP) Report Years Considered
Figure 9. Global Community Acquired Pneumonia (CAP) Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Community Acquired Pneumonia (CAP) Market Share by Regions: 2020 VS 2026
Figure 11. Global Community Acquired Pneumonia (CAP) Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Community Acquired Pneumonia (CAP) Market Share by Players in 2019
Figure 14. Global Top Community Acquired Pneumonia (CAP) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Community Acquired Pneumonia (CAP) as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Community Acquired Pneumonia (CAP) Revenue in 2019
Figure 16. North America Community Acquired Pneumonia (CAP) Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Community Acquired Pneumonia (CAP) Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Community Acquired Pneumonia (CAP) Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Community Acquired Pneumonia (CAP) Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Community Acquired Pneumonia (CAP) Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Community Acquired Pneumonia (CAP) Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Community Acquired Pneumonia (CAP) Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed
院内肺炎予防の世界市場（～2026年） HAP is defined as a lower respiratory infection, which does not incubate at the time of hospital admission but presents clinically 2 or more days after hospitalization.Incidence of HAP is more prevalent in the medical and surgical Intensive Care Units, and results in additional cost to the healthcar…- 市中型MRSA感染症治療薬の世界市場（～2026年） Market Analysis and Insights: Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market The global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at…
- 院内肺炎（HAP）治療薬の世界市場（～2026年） HAP is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and mainly affects …
- 院内肺炎治療薬の世界市場（～2026年） Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48–72 hours after being admitted. It is thus distinguished from community-acquired pneumonia. It is usually caused by a bacterial infection, rather than a virus. Market An…
- 後天性孤児造血疾患治療薬の世界市場（～2026年） Acquired orphan blood disease is a type of rare blood disorder, which occurs due to the presence of insufficient amount of red blood cells in the blood. This disease is characterized by the body’s inability to produce red blood cells. Moreover, improper functioning of bone marrow also leads to lack …